Emactuzumab
Emactuzumab: A Novel Therapeutic Approach Targeting CSF-1R[edit | edit source]
Emactuzumab (also known by its experimental code name RG-7155) is a humanized monoclonal antibody, which holds potential as a therapeutic agent, owing to its specific action against the colony-stimulating factor 1 receptor (CSF-1R). This molecule, predominantly expressed on macrophages, plays a pivotal role in various pathologies, including certain tumor types. Emactuzumab's distinctive mechanism of action, primarily through the disruption of the CSF-1/CSF-1R axis, offers a novel therapeutic pathway in oncology.
CSF-1/CSF-1R Axis: A Brief Overview[edit | edit source]
The CSF-1/CSF-1R signaling axis is central to the differentiation, proliferation, and survival of mononuclear phagocytes. Notably:
- CSF-1 (Colony-stimulating factor 1): A primary growth factor controlling the production and functional programming of monocytes and macrophages[1].
- CSF-1R (Colony-stimulating factor 1 receptor): A tyrosine-protein kinase receptor crucial for macrophage function, mutations in which have been implicated in certain cancers[2].
Mechanism of Action[edit | edit source]
Emactuzumab, by specifically targeting CSF-1R, achieves two primary therapeutic outcomes:
- Inhibition of Tumor-associated Macrophages (TAMs): Emactuzumab obstructs the recruitment and survival of TAMs, which are typically associated with tumor growth, angiogenesis, and metastasis[3].
- Suppression of d-TGCT Growth: Through the interference of the CSF-1/CSF-1R axis, Emactuzumab impedes the growth of diffuse-type tenosynovial giant cell tumors (d-TGCT), a rare joint tumor[4].
Clinical Implications[edit | edit source]
Emactuzumab's preclinical and early-phase clinical evaluations have underscored its potential:
- Efficacy: Profound antitumor effects observed in d-TGCT, with considerable tumor volume reductions.
- Safety Profile: Generally well-tolerated in patients, with side effects deemed manageable.
Moreover, the drug's unique mechanism of action suggests its applicability might extend to other tumors exhibiting aberrant CSF-1/CSF-1R signaling[5].
Conclusion[edit | edit source]
Emactuzumab encapsulates the strides made in molecular-targeted therapies in oncology, with a focus on leveraging the tumor microenvironment. While further research will establish its precise clinical utility, Emactuzumab's pioneering approach illuminates new avenues for the therapeutic management of d-TGCT and potentially other CSF-1R-associated malignancies.
References[edit | edit source]
- ↑ Ridge, S. A., et al. (1990). Plasmacytoma variants of myeloma have a distinct gene expression profile and can be used to predict outcome. British journal of haematology, 90(2), 258-266.
- ↑ Guo, Y., et al. (2017). CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer research, 77(18), 5054-5065.
- ↑ DeNardo, D. G., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer discovery, 1(1), 54-67.
- ↑ Cassier, P. A., et al. (2015). CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. The Lancet Oncology, 16(8), 949-956.
- ↑ Ries, C. H., et al. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer cell, 25(6), 846-859.
Emactuzumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Admin, Prab R. Tumpati, MD